Figure 7
DCZ3301 inhibits the growth of tumor in a xenograft mouse model and synergizes with panobinostat in DLBCL cell lines. OCI-LY8 cells (2.0 × 106) were subcutaneously injected into the flank of 6-week-old nude mice and, respectively, administered 5% DMSO and saline to the controlled group or DCZ3301 (40 mg/kg) to the drug-treated group for 12 days (n=3/group). (a) The tumor samples were collected and imaged using a digital camera. (b) The tumor volume was measured each day for 12 days (*P<0.05). (c) The weight of mice was measured each day for 12 days. (d) H&E, TUNEL and anti-phospho-STAT3 antibody staining of tumor tissues from controlled or DCZ3301-treated mice were pictured (original magnification: × 400). (e) OCI-LY8 cells were treated with panobinostat or panobinostat at a constant concentration of DCZ3301 or (f) were treated with DCZ3301 or DCZ3301 at a constant concentration of panobinostat and then the cell proliferation was detected using CCK-8 assay after culturing for 48 h. Data analyzed by the Calcusyn software shows the synergistic activity of DCZ3301 and panobinostat against DLBCL cell lines. Combination index <1 indicates synergy
